The U.S. Court of Appeals for the Federal Circuit issued a ruling on February 19, 2026 that upheld a prior district‑court decision finding that Teva’s labeling and prescribing information for its generic version of Korlym (mifepristone) does not infringe Corcept Therapeutics’ patents covering the drug’s dosing when combined with strong CYP3A inhibitors. The decision removes a significant legal hurdle that had limited Teva’s ability to market its Korlym generic in the United States.
Teva’s Q4 2025 earnings report, released on January 28, 2026, showed earnings per share of $0.96 versus analyst expectations of $0.65 and revenue of $4.71 billion versus $4.36 billion expected. The ruling is expected to support Teva’s strategy to expand its specialty‑generic portfolio, although the company’s 2026 revenue and earnings guidance remain below analyst forecasts, reflecting broader market headwinds and the need to balance growth with cost discipline.
Corcept Therapeutics relies almost entirely on Korlym for revenue, with the drug accounting for roughly 100 % of the company’s sales. The Federal Circuit’s decision eliminates the patent protection that has kept generic competitors out of the market, exposing Corcept to the risk of early generic entry and potential erosion of its high‑margin product. The company’s Q4 2025 earnings, due on February 25, 2026, are expected to reflect the impact of this loss of exclusivity.
Following the ruling, Corcept’s stock fell more than 20 % on February 19, 2026, reflecting investor concern over the loss of its sole revenue source. Teva’s shares remained largely flat, indicating that the market viewed the ruling as a positive development for the generic’s commercial prospects but tempered by the company’s lower 2026 guidance.
Corcept CEO Joseph K. Belanoff expressed disappointment, stating that the company would “vigorously defend our rights” and was “considering the best way to pursue judicial review” of the decision. No direct quote from Teva’s leadership was provided in the fact‑check report.
The ruling has strategic implications for both firms. For Teva, it clears a major legal obstacle that could accelerate sales of its Korlym generic and strengthen its position in the specialty‑generic segment, though the company must navigate a challenging 2026 outlook. For Corcept, the loss of patent protection threatens its revenue base and underscores the urgency of advancing its pipeline, particularly the relacorilant program, to diversify beyond its single‑product dependence.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.